Diflunisal Offlabel denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for diflunisal offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Imposes Quantity Limits on Off-Label Diflunisal

For medications used off-label, Humana commonly applies quantity limits as an additional utilization management layer. A quantity-limit denial means the plan will only cover a defined supply per dispensing period and the submitted prescription exceeds that limit. For an off-label use like diflunisal in amyloid-related conditions, the prescribed regimen may not match the default quantity Humana has coded into its system, leading to an automatic denial at the pharmacy.

## Why This Is Appealable

Quantity limits are a plan design decision, not an immutable clinical fact. When a prescriber determines that a patient's clinical situation requires a quantity that differs from the plan's default, the prescriber can request a quantity-limit exception. This is a separate appeal pathway from a standard PA, though both involve demonstrating clinical necessity. Quantity-limit exceptions are overturned regularly when the clinical rationale is well-documented.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Humana must respond within the applicable timeframe for the type of request (prospective, urgent, or post-service).
• External review (ACA §2719): If internal appeal fails, request independent external review within 4 months. The IRO's decision binds Humana.
• ERISA §503 (self-funded plans): Full-and-fair review rights apply; procedural violations are reviewable in federal court.
• Expedited review: Request if delay poses a health risk.

## Documentation to Gather

1. Prescriber letter explaining the quantity — the prescriber should explain why the prescribed quantity is medically necessary, referencing the dosing rationale from the FDA-approved prescribing information or the published clinical evidence supporting this off-label use. The letter should not simply restate the prescription; it should explain the clinical reasoning. 2. Relevant prescribing label or compendia entry — showing that the prescribed regimen is consistent with recognized dosing guidance. 3. Diagnosis and severity documentation — chart notes, test results, and assessments confirming the condition and its severity. 4. Prior-treatment history — documenting what has been tried previously and why the current regimen is necessary. 5. Pharmacy records — showing the dispensing history if the patient has been stable on this quantity.

## Criteria-Mapping Structure

Obtain Humana's current quantity-limit exception criteria from its medical policy or pharmacy benefit policy. Map each criterion to your documentation:

| Quantity-Limit Exception Criterion | Your Documentation | |---|---| | Clinical justification for quantity above default | [Prescriber letter] | | Diagnosis confirmed | [Chart / test results] | | Regimen consistent with recognized prescribing guidance | [Label / compendia citation] | | Prior therapies or dose adjustments documented | [Treatment history] |

Always verify the current quantity-limit exception policy directly with Humana before submitting — the specific criteria are what reviewers apply.